{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:00Z","timestamp":1791559380339,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.7759\/cureus.113910","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:37:46Z","timestamp":1785821866000},"source":"Crossref","is-referenced-by-count":1,"title":["Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions"],"prefix":"10.7759","author":[{"given":"Abdulmuhsun H","family":"Al-Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1608657","article-title":"A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide","volume":"16","author":"Huang M","year":"2025","unstructured":"Huang M, Liu G, Zhang C, Wang Y, Liu S, Zhao J. A retrospective observational study on case reports of adverse drug reactions (ADRs) to tirzepatide. Front Pharmacol. 2025, 16:1608657. 10.3389\/fphar.2025.1608657","journal-title":"Front Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2020.100472","article-title":"World Allergy Organization anaphylaxis guidance 2020","volume":"13","author":"Cardona V","year":"2020","unstructured":"Cardona V, Ansotegui IJ, Ebisawa M, et al.. World Allergy Organization anaphylaxis guidance 2020. World Allergy Organ J. 2020, 13:100472. 10.1016\/j.waojou.2020.100472","journal-title":"World Allergy Organ J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker MS","year":"2020","unstructured":"Shaker MS, Wallace DV, Golden DB, et al.. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020, 145:1082-123. 10.1016\/j.jaci.2020.01.017","journal-title":"J Allergy Clin Immunol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12418","article-title":"Epidemiology of anaphylaxis","volume":"45","author":"Tejedor Alonso MA","year":"2015","unstructured":"Tejedor Alonso MA, Moro Moro M, M\u00fagica Garc\u00eda MV. Epidemiology of anaphylaxis. Clin Exp Allergy. 2015, 45:1027-39. 10.1111\/cea.12418","journal-title":"Clin Exp Allergy"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-021-01006-x","article-title":"Fatal anaphylaxis: epidemiology and risk factors","volume":"21","author":"Mikhail I","year":"2021","unstructured":"Mikhail I, Stukus DR, Prince BT. Fatal anaphylaxis: epidemiology and risk factors. Curr Allergy Asthma Rep. 2021, 21:28. 10.1007\/s11882-021-01006-x","journal-title":"Curr Allergy Asthma Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2023.2247984","article-title":"Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!","volume":"22","author":"Patoulias D","year":"2023","unstructured":"Patoulias D, Caprio M, Stoian AP, Rizzo M. Tirzepatide and glucagon-like peptide-1 receptor agonists: safety always comes first!. Expert Opin Drug Saf. 2023, 22:763-5. 10.1080\/14740338.2023.2247984","journal-title":"Expert Opin Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.50112","article-title":"Tirzepatide-induced biphasic anaphylactic reaction: a case report","volume":"15","author":"He Z","year":"2023","unstructured":"He Z, Tabe AN, Rana S, King K. Tirzepatide-induced biphasic anaphylactic reaction: a case report. Cureus. 2023, 15:e50112. 10.7759\/cureus.50112","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51460","article-title":"A case report of systemic allergic reaction to the dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonist tirzepatide","volume":"16","author":"Le TT","year":"2024","unstructured":"Le TT, Minh LH, Devi P, Islam N, Sachmechi I. A case report of systemic allergic reaction to the dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 receptor agonist tirzepatide. Cureus. 2024, 16:e51460. 10.7759\/cureus.51460","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/494172-suspected-biphasic-anaphylaxis-following-the-first-known-dose-of-tirzepatide-a-case-report-and-brief-review-of-reported-hypersensitivity-reactions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:37:47Z","timestamp":1785821867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/494172-suspected-biphasic-anaphylaxis-following-the-first-known-dose-of-tirzepatide-a-case-report-and-brief-review-of-reported-hypersensitivity-reactions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.113910","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}